32 results
8-K
PNT
POINT Biopharma Global Inc.
13 Jun 23
Departure of Directors or Certain Officers
4:45pm
on the Company’s Nominating and Corporate Governance Committee.
Dr. Martell is a pharmaceutical executive. She started her pharmaceutical career at Pfizer
ARS
2022 FY
PNT
POINT Biopharma Global Inc.
1 May 23
Annual report to shareholders
1:52pm
Inspections 100 Part III 101 Item 10. Directors, Executive Officers and Corporate Governance 101 Item 11. Executive Compensation 101 Item 12. Security …
PART III Item 10. Directors, Executive Officers and Corporate Governance Incorporated herein by reference to our definitive proxy statement for our
424B3
PNT
POINT Biopharma Global Inc.
11 Jul 22
Prospectus supplement
4:32pm
with the SEC on March 25, 2022, entitled “Item 10. Directors, Executive Officers and Corporate Governance,” “Item 11. Executive Compensation” and “Item 13
POS AM
PNT
POINT Biopharma Global Inc.
1 Jul 22
Prospectus update (post-effective amendment)
4:17pm
with the SEC on March 25, 2022, entitled “Item 10. Directors, Executive Officers and Corporate Governance,” “Item 11. Executive Compensation” and “Item 13
DEF 14A
lp1 sywdeyr
28 Apr 22
Definitive proxy
8:36am
424B3
bf6r jmk3rh
31 Mar 22
Prospectus supplement
11:42am
POS AM
9kagc
25 Mar 22
Prospectus update (post-effective amendment)
8:41am
424B3
n9b6hci h8km
5 Aug 21
Prospectus supplement
4:26pm
8-K
EX-3.2
8qup5wt21bs7o
1 Jul 21
Unaudited pro forma condensed combined financial statements
12:00am
8-K
yvy6l
1 Jul 21
Unaudited pro forma condensed combined financial statements
12:00am
424B3
odw 8ugxznnc6c
9 Jun 21
Prospectus supplement
4:42pm
S-4/A
x8mp1
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
S-4
ez8ia ngc3v4w67o
22 Mar 21
Registration of securities issued in business combination transactions
9:52pm
8-K/A
EX-2.1
oy5c8pjv72mcy
18 Mar 21
Financial Statements and Exhibits
9:08am
10-K
pxp33bcc80zm euf
5 Mar 21
Annual report
8:13am